A Trial Evaluating the Activity and Safety of Combination Between Cabozantinib and Temozolomide in Lung and GEP-NENS Progressive After Everolimus, Sunitinib or PRRT (CABOTEM)

The aim of CABOTEM study is to demonstrate the safety and activity of the Cabozantinib and Temozolomide combination in Lung and GEP-NENs patients, progressing after a first line therapy, including target therapies (everolimus, sunitinib) and / or chemotherapy, in the approved setting.

Trial Details

NCT ID

NCT04893785

Phase

PHASE2

Sponsor

National Cancer Institute, Naples

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

Cabozantinib and Temozolomide

Locations (sample)

Naples, Campania, Italy|40.85216,14.26811

Key Eligibility Criteria

18 years and older patients.
Signed informed consent prior to initiation of any study-specific procedures or treatment, as confirmation of the patient's awareness and willingne…
Documented histological or cytological diagnosis of well differentiated Lung and GEP-NENs (NET G1, NET G2, NET G3 in WHO 2017 classification) progr…
Subjects must have evidence of progressed disease, radiologically documented in the 12 months previous study entry.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →